Marking the Way for Alzheimer's Drugs

By David Williamson | More Articles April 19, 2013 |

Eli Lilly (NYSE: LLY) has been rolling out diabetes and oncology drugs of late. In this video, David Williamson highlights Lilly's Alzheimer's drugs. Recently, Lilly bought two German imaging companies for undisclosed sums. It's not clear what these companies will do, but they could play a role in the detection, treatment, and monitoring of Alzheimer's, particularly the so-called amyloid plaques that characterize the disease. Also, Lilly has two different drugs targeting amyloid production in the brain, which may help slow or stop progression of the disease. Given the aging of the American population, if these drugs prove effective, they could be big revenue generators for Lilly.

Is Eli Lilly a buy or sell? With two of its top three drugs poised to lose patent protection this year, is Eli Lilly a dividend stock headed nowhere fast? In a new premium report, The Motley Fool's senior pharmaceuticals analyst breaks down all of Lilly's moving parts, including an in-depth analysis of the company's must-know opportunities, and reasons to buy and sell today. To find out more,click here to claim your copy today.

Original post:
Marking the Way for Alzheimer's Drugs